| Serial Number | 90281316 |
| Word Mark | MATRIPTIMAB |
| Filing Date | Tuesday, October 27, 2020 |
| Status | 602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE |
| Status Date | Thursday, July 8, 2021 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | NOT AVAILABLE |
| Goods and Services | Matriptimab is a novel antibody-drug conjugate that targets activated matriptase, a tumor antigen expressed almost exclusively on cancer cells |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, December 17, 2020 |
| Primary Code | 005 |
| First Use Anywhere Date | Thursday, March 22, 2018 |
| First Use In Commerce Date | Thursday, March 22, 2018 |
| Party Name | Xiconic Pharmaceuticals, LLC |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 16 - Limited Liability Company |
| Address | New York, NY 10001 |
| Event Date | Event Description |
| Friday, July 9, 2021 | ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND |
| Thursday, July 8, 2021 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE |
| Wednesday, December 23, 2020 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, December 23, 2020 | NON-FINAL ACTION E-MAILED |
| Wednesday, December 23, 2020 | NON-FINAL ACTION WRITTEN |
| Wednesday, December 23, 2020 | ASSIGNED TO EXAMINER |
| Thursday, December 17, 2020 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
| Friday, October 30, 2020 | NEW APPLICATION ENTERED IN TRAM |